Show news: from last 30 days (default), 60 days, 90 days, last visit or all

Cochrane review: olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults

26th September 2018

In this review, the authors concluded that oral olanzapine probably increases the likelihood of not being nauseous or vomiting during chemotherapy from 25% to 50% in adults with solid tumours, in addition to standard therapy, compared to placebo or no treatment.

There is uncertainty whether it increases serious undesirable effects. It may increase the likelihood of other undesirable effects, e.g. somnolence and fatigue. There is uncertainty about relative benefits and harms of 5mg versus 10mg.

Only RCTs describing oral administration were found. The authors noted that the findings of this review cannot be extrapolated to provide evidence about the efficacy and safety of any injectable form (intravenous, intramuscular or subcutaneous) of olanzapine.

click here to view